bay-x-7195 has been researched along with Lung-Neoplasms* in 1 studies
1 other study(ies) available for bay-x-7195 and Lung-Neoplasms
Article | Year |
---|---|
Antagonism of leukotriene responses in human airways by BAY x7195.
Contractions induced by leukotriene and anti-IgE (sheep antiserum to human IgE) were antagonized by pretreatment of human airways with the cysteinyl leukotriene receptor antagonist BAY x7195 ((4S)-[4-carboxyphenylthio]-7-[4-(4-phenoxybutoxy)-phenyl]-h ept-5-(z)- enoic acid). However, this receptor antagonist did not inhibit either leukotriene D4- or leukotriene C4-induced contractions in human pulmonary veins. The pA2 value for BAY x7195 in human airways against leukotriene D4 was 7.83 +/- 0.16 with a slope of 1.07 +/- 0.15 (means +/- S.E.M; n = 11). The IC50 value for BAY x7195 in human airways contracted with anti-IgE was 0.31 +/- 0.08 microM (n = 11). These results were comparable to those obtained with ICI 204,219 (4-(5-cyclopentyl-oxycarbonylamino-1-methylindol-3-ylmeth yl)-3-methoxy-N-otolyl - sulfonylbenzamide). These data demonstrate that BAY x7195 is a potent selective leukotriene receptor antagonist which may block allergic reactions in the lung. Topics: Antibodies, Anti-Idiotypic; Bronchodilator Agents; Female; Humans; Hydroxy Acids; Immunoglobulin E; Indoles; Leukotriene C4; Leukotriene D4; Lung Neoplasms; Male; Middle Aged; Muscle Contraction; Muscle, Smooth; Phenylcarbamates; Pulmonary Veins; Sulfonamides; Tosyl Compounds | 1995 |